These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 977945)

  • 21. Functional affinity constants of the reaction between 125I-labelled C1q and C1q binders and their use in the measurement of plasma C1q concentrations.
    Hughes-Jones NC
    Immunology; 1977 Feb; 32(2):191-8. PubMed ID: 844894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C1 and human platelets. III. Role of C1 subcomponents in platelet aggregation induced by aggregated IgG.
    Wautier JL; Souchon H; Solal LC; Peltier AP; Caen JP
    Immunology; 1976 Oct; 31(4):595-9. PubMed ID: 185144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemolytic efficiency of cell-bound IgM: evidence that IgM-C1 complexes activate C4 molecules not hemolytic with homologous C2--C9.
    Ejzemberg R; Borsos T
    J Immunol; 1982 Apr; 128(4):1600-2. PubMed ID: 7061844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
    Heinz HP; Burger R; Golan MD; Loos M
    J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement.
    Heinz HP; Dlugonska H; Rüde E; Loos M
    J Immunol; 1984 Jul; 133(1):400-4. PubMed ID: 6609989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of HIV-1 protease cleavage site in human C1-inhibitor.
    Gerencer M; Burek V
    Virus Res; 2004 Sep; 105(1):97-100. PubMed ID: 15325085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune complex mediated activation of the classical complement pathway.
    Borsos T
    Behring Inst Mitt; 1989 Jul; (84):93-101. PubMed ID: 2478118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement-mediated hemolytic activity of succinylated concanavalin A: preparation and activity of cell intermediates.
    Langone JJ; Ejzemberg R
    J Immunol; 1985 Feb; 134(2):1110-4. PubMed ID: 3965569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
    Doekes G; van Es LA; Daha MR
    J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional analysis of activated C1s, a subcomponent of the first component of human complement, by monoclonal antibodies.
    Matsumoto M; Nagaki K
    J Immunol; 1986 Nov; 137(9):2907-12. PubMed ID: 2428878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man.
    Atkinson JP; Frank MM
    J Clin Invest; 1974 Aug; 54(2):339-48. PubMed ID: 4847248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.
    Ziccardi RJ
    J Immunol; 1985 Apr; 134(4):2559-63. PubMed ID: 3973388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1.
    Tenner AJ; Frank MM
    J Immunol; 1986 Jul; 137(2):625-30. PubMed ID: 3722818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.
    Wisnieski JJ; Knauss TC; Yike I; Dearborn DG; Narvy RL; Naff GB
    J Immunol; 1994 Mar; 152(6):3199-209. PubMed ID: 8144914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
    Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
    Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
    Schreiber AD; Frank MM
    J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysis of C1Q-coated chicken erythrocytes by human lymphoblastoid cell lines.
    Ghebrehiwet B; Müller-Eberhard HJ
    J Immunol; 1978 Jan; 120(1):27-32. PubMed ID: 564373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates.
    Veerhuis R; van Es LA; Daha MR
    Immunology; 1985 Apr; 54(4):801-10. PubMed ID: 3872261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.